NCT00113802 2021-08-19
Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia
Gilead Sciences
Phase 2 Terminated
Clinical Trials
7 trialsNCT00301821 2019-10-09
Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00945815 2017-11-06
S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
SWOG Cancer Research Network
Phase 2 Completed
NCT00553501 2016-07-06
Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00941928 2014-05-22
Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00042913 2013-12-19
Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00044902 2007-12-28
Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)
Amgen
Phase 2 Completed